Introduction. The use of polymeric biodegradable nanoparticles (NP) as drug delivery systems is a promising approach to overcome histohematomatic barriers. Thus, poloxamer 188-coated poly (lactide-co-glycolide) (PLGA) NP are able to overcome blood-brain barrier and to deliver therapeutic agents, in particular doxorubicin, into intracranial tumour upon intravenous administration. It is important to evaluate NP interaction with blood components in preclinical studies. The objective of the study was to investigate cytotoxicity and hemocompatibility of doxorubicin-loaded PLGA NP (Dox-PLGA NP), to essess NP uptake by glioblastoma cells. Materials and methods. The influence of NP on coagulation cascade was evaluated by prothrombin time measuring before and after plasma incubation with NP. To assess NP thrombogenicity the platelet activation level was determined by flow cytometry. The NP hemolytic activity (released hemoglobin concentration) was measured spectrophotometrically. NP cytotoxicity was determined by MTS assay. NP uptake by human glioblastoma cells was evaluated by flow cytometry. Results. Dox-PLGA NP did not influence blood coagulation time and thrombocyte activity at concentrations up to 100 mcg/mL: PT values were 12–15 s for all tested samples, and P-selectin expression level did not exceed 15 %. All samples were not hemolytic after 3 h of incubation. Cytotoxicity of doxorubicin released from PLGA NP on glioma U87MG cells was comparable to that of free doxorubicin. As shown by flow cytometry Dox-PLGA NP were efficiently internalized into the cells. Conclusion. The study of hemocompatibility confirmed the safety of Dox-PLGA NP: NP did not influence blood coagulation system and did not induce hemolysis. NP were efficiently internalized into the human glioblastoma cells and produced considerable antitumor effect in vitro.

В статье приведены результаты исследования включения в липидные наночастицы — липосомы фармацевтически активных субстанций (иринотекана, оксалиплатина, цитохрома С, доксорубицина, кверцетина и др.). Рассмотрены основные методы включения субстанций в липосомы: метод липидной пленки, методы градиента и химической связи. Приведены основные условия включения лекарственных веществ в липосомы. Обсуждаются вопросы определения включения в липосомы, получения и контроля готовых лекарственных липосомальных препаратов. Полученные препараты находятся на различных стадиях доклинических и клинических испытаний. Ряд предложенных препаратов зарегистрирован и используются в медицинской практике более 25 лет.

The results of many years of scientific research in the field of physico-chemical biology and its most important direction - lipidology, conducted by the leading scientific school under the leadership of Academician RAS Vitaly I. Shvets, are reported. On the creation of synthetic, biotechnological methods for obtaining lipids, with the possibility of their practical use by designing on this basis effective diagnostic and medicinal products and application in practical medicine. The further development and use of methods of bionanotechnology for the development of modern medicines for directed action on the basis of increasing the effectiveness of classical drugs by their incorporation into nanocontainers is described. It is reported on the development of technologies for obtaining nanoscale forms of drugs, the study of their pharmacological properties and use in medical practice. Information is provided on the preparation of liposomal antitumor, hepatoprotective, anti-tuberculosis, cardiac preparations based on the proposed echnologies, the study of properties and the use for therapeutic purposes. The technologies for obtaining and conducting biological studies of nanoforms based on copolymers of lactic and glycolic acids of antineoplastic, anti-inflammatory, antibacterial and a number of other drugs have been developed: It has been shown that the use of nanosized drugs can lead to a significant increase in the pharmacological effect due to various factors. It was noted that during the construction of the drug for the treatment of Parkinson's disease, the contents of liposomes loaded with dopamine pass through the blood-brain barrier almost 100 times better than individual dopamine molecules. Finding a substance in nanoparticles reduces its toxicity primarily due to the effect of "passive targeting". The prolonged action of medicinal substances enclosed in nanoparticles is discussed, due to their gradual release. It is noted that the targeted delivery of nanoparticles makes it possible to increase the effectiveness of the drugs by an order of magnitude. It is reported on the drug-delivery technology in the field of oncology and the use of the method of selective delivery of cytostatics to tumor tissues using the receptor-mediated endocytosis. Biological and pharmacological studies based on nanopoporous silicon on the creation of liposomal drugs for the treatment of cancer, cardiological pathologies, tuberculosis are carried out. Data on the work of the scientific and educational center for training specialists in the field of biotechnology and pharmacy are given.

The neuroprotective activity of recombinant human erythropoietin (rhEPO) loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles has been observed in rats with model intracerebral post-traumatic hematoma (hemorrhagic stroke). It is established that rhEPO-loaded PLGA nanoparticles produce a neuroprotective effect in rats with hemorrhagic stroke, which is manifested by reduced number of lethal outcomes and animals with neurological disorders. Treatment with rhEPO-loaded PLGA prevented amnesia of passive avoidance reflex (PAR), which was produced by the hemorrhagic stroke, and reduced the area of brain damage caused by the intracerebral hematoma. These effects were recorded during one-week observation period. Native rhEPO exhibited a similar, but much less pronounced effect on the major disorders caused by the model hemorrhagic stroke in rats.

В обзоре рассмотрены возможные механизмы транспорта лекарственных веществ через гематоэнцефалический барьер в составе полимерных наночастиц. Представлены экспериментальные данные о влиянии поверхностно-активных веществ и аполипопротеинов плазмы крови на способность полимерных наночастиц доставлять лекарственные вещества в мозг.

This study was aimed at developing a method for obtaining a nanosomal colloidal form of low-sialylated human erythropoietin (lsHEP) possessing neurotropic (antihemorrhage) activity. Parameters of HEP adsorption on nanoparticles of (i) homopolymer of lactic acid and (ii) copolymer of lactic and glycolic acids, average sizes of these nanoparticles, and aggregation stability of obtained complexes have been determined. The most effective adsorption (>80%) was achieved for a 50/50 copolymer of lactic and glycolic acids. Experiments on rats with intracerebral post-traumatic hematoma model showed that the obtained nanosomal lsHEP exhibited a significant neuroprotective effect, which was manifested by 40% reduced loss of test animals (77.8% survival). Chronic administration of nanosomal lsHEP did not influence hemopoiesis in the experimental animals.

The neuroprotective activity of recombinant human erythropoietin (r-HuEpo) sorbed on poly(butyl)cyanoacrilate nanoparticles (EPO-PBCA) and on polylactic-co-glycolic acid nanoparticles (EPO-PLGA) has been studied on Wistar rats with intracerebral post-traumatic hematoma (model of hemorrhagic stroke) (IPH-HS) in comparison to native r-HuEpo. It is established that EPO-PBCA produced a protective effect in rats after IPH-HS that was manifested by a decrease in the number of animals with neurological disorders such as circus movement, paresis, and paralysis of hind limbs; the drug also improved coordination (rotating rod test), reduced the number of lost animals, and decreased the loss weight among survived rats. In addition, EPO-PBCA optimized the research behavior of rats with IPH-HS in the open field test and prevented amnesia of passive avoidance reflex (PAR), which was caused by the IPH-HS. These effects were manifested during a two-week observation period. EPO-PLGA has a similar but much less pronounced effect on the major disorders caused by IPH-HS. The efficiency of native r-HuEpo as a neuropotective agent was insignificant and only manifested by decrease in the number of lost animals with IPH-HS.